

Minesh P Mehta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4699731/publications.pdf>

Version: 2024-02-01

679
papers

52,567
citations

1163

111
h-index

1851

209
g-index

748
all docs

748
docs citations

748
times ranked

28929
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 699-708.	13.9	2,279
2	Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. <i>Lancet</i> , The, 2004, 363, 1665-1672.	6.3	2,248
3	Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, 419-425.	0.8	1,205
4	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. <i>Journal of Clinical Oncology</i> , 2013, 31, 337-343.	0.8	968
5	A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 510-514.	0.4	907
6	Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3810-3816.	0.8	894
7	Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 655-661.	0.4	873
8	Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4085-4091.	0.8	820
9	Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. <i>New England Journal of Medicine</i> , 2016, 374, 1344-1355.	13.9	814
10	Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. <i>Neuro-Oncology</i> , 2013, 15, 1429-1437.	0.6	746
11	Correlation of O ⁶ -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. <i>Journal of Clinical Oncology</i> , 2008, 26, 4189-4199.	0.8	725
12	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , The, 2015, 16, e270-e278.	5.1	711
13	Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. <i>Journal of Clinical Oncology</i> , 2006, 24, 2707-2714.	0.8	678
14	Estimating Survival in Patients With Lung Cancer and Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 827.	3.4	543
15	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
16	Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 853-860.	0.4	527
17	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 157-165.	0.8	523
18	A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 35, 27-35.	0.4	517

#	ARTICLE	IF	CITATIONS
19	A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 519-526.	0.4	515
20	Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. <i>Journal of Clinical Oncology</i> , 2006, 24, 5711-5715.	0.8	500
21	Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. <i>Journal of Clinical Oncology</i> , 2020, 38, 1019-1029.	0.8	483
22	American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 326-332.	0.4	473
23	The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 45-68.	1.4	446
24	Image guidance for precise conformal radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 89-105.	0.4	445
25	Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases. <i>Journal of Clinical Oncology</i> , 2003, 21, 2529-2536.	0.8	438
26	Whole-Brain Radiotherapy in the Management of Brain Metastasis. <i>Journal of Clinical Oncology</i> , 2006, 24, 1295-1304.	0.8	431
27	Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 871-881.	0.6	407
28	Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08. <i>Clinical Cancer Research</i> , 2006, 12, 4899-4907.	3.2	404
29	Tomotherapy. <i>Seminars in Radiation Oncology</i> , 1999, 9, 108-117.	1.0	390
30	Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2008, 10, 162-170.	0.6	362
31	The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 33-43.	1.4	361
32	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of <i>IDH1</i> . <i>Journal of Clinical Oncology</i> , 2014, 32, 783-790.	0.8	356
33	An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. <i>Cancer Discovery</i> , 2011, 1, 442-456.	7.7	346
34	Current Management of Brain Metastases, With a Focus on Systemic Options. <i>Journal of Clinical Oncology</i> , 2005, 23, 6207-6219.	0.8	334
35	A multigene predictor of outcome in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 49-57.	0.6	334
36	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 37-46.	0.4	321

#	ARTICLE	IF	CITATIONS
37	Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 2111-2117.	0.4	321
38	Why avoid the hippocampus? A comprehensive review. <i>Radiotherapy and Oncology</i> , 2010, 97, 370-376.	0.3	313
39	Hippocampal-Sparing Whole-Brain Radiotherapy: A "How-To" Technique Using Helical Tomotherapy and Linear Accelerator-Based Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1244-1252.	0.4	305
40	Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 458-471.	7.7	304
41	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 348-354.	0.4	303
42	Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802. <i>Journal of Clinical Oncology</i> , 2012, 30, 3065-3070.	0.8	301
43	Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function. <i>Journal of Clinical Oncology</i> , 2007, 25, 1260-1266.	0.8	299
44	The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 103-114.	1.4	283
45	Defining the role of radiosurgery in the management of brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 24, 619-625.	0.4	282
46	EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antiplogenic Therapy. <i>Science Signaling</i> , 2009, 2, ra82.	1.6	282
47	The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 17-32.	1.4	277
48	A challenge to traditional radiation oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1241-1256.	0.4	273
49	Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. <i>Journal of Neurosurgery</i> , 2008, 109, 835-841.	0.9	264
50	Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 426-434.	0.4	261
51	Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 64-70.	0.4	259
52	The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 779-788.	0.4	255
53	A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1312-1318.	0.4	254
54	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. <i>Neuro-Oncology</i> , 2010, 12, 95-103.	0.6	252

#	ARTICLE	IF	CITATIONS
55	A new approach to dose escalation in non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 23-33.	0.4	241
56	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. <i>Journal of Clinical Oncology</i> , 2020, 38, 3773-3784.	0.8	223
57	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	0.6	209
58	Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2689-2695.	0.8	204
59	Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 623-630.	0.4	203
60	A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1. <i>Neuro-Oncology</i> , 2006, 8, 189-193.	0.6	200
61	A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 445-454.	0.4	195
62	Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms. <i>Clinical Cancer Research</i> , 2006, 12, 4738-4746.	3.2	195
63	American Society for Therapeutic Radiology and Oncology* and American College of Radiology Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1026-1032.	0.4	191
64	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). <i>Neuro-Oncology</i> , 2010, 12, 855-861.	0.6	184
65	Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. <i>Journal of Neurosurgery</i> , 2018, 129, 35-47.	0.9	178
66	Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397). <i>Journal of Clinical Oncology</i> , 2005, 23, 8870-8876.	0.8	176
67	Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 589-597.	0.4	176
68	Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 931-941.	0.4	175
69	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. <i>Neuro-Oncology</i> , 2019, 21, 167-178.	0.6	173
70	Distribution of Brain Metastases in Relation to the Hippocampus: Implications for Neurocognitive Functional Preservation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 971-977.	0.4	168
71	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e487-e493.	0.4	168
72	Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. <i>Radiotherapy and Oncology</i> , 2010, 95, 327-331.	0.3	166

#	ARTICLE	IF	CITATIONS
73	Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2648-2653.	0.8	166
74	Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2010, 96, 211-217.	1.4	163
75	Presentation, patterns of care, and survival in patients with brain metastases. <i>Cancer</i> , 2011, 117, 2505-2512.	2.0	163
76	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	3.9	163
77	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 812-816.	0.4	163
78	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 47-55.	0.4	162
79	A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. <i>Cancer</i> , 2016, 122, 1483-1501.	2.0	162
80	Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non-small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1069-1076.	0.4	161
81	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	0.8	159
82	Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 526-531.	0.4	155
83	Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 2305-2311.	0.8	151
84	Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3760-3767.	0.8	151
85	Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3651-3656.	0.8	151
86	Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy. <i>Technology in Cancer Research and Treatment</i> , 2002, 1, 311-316.	0.8	149
87	Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and tomotherapy. <i>Radiotherapy and Oncology</i> , 2011, 100, 241-246.	0.3	148
88	Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 541-549.	0.4	146
89	Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points. <i>Journal of Clinical Oncology</i> , 2002, 20, 3445-3453.	0.8	141
90	The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 71-83.	1.4	141

#	ARTICLE	IF	CITATIONS
91	Association of <i>MGMT</i> Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide. <i>JAMA Oncology</i> , 2018, 4, 1405.	3.4	141
92	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , 2014, 16, 567-578.	0.6	140
93	Integral radiation dose to normal structures with conformal external beam radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 962-967.	0.4	139
94	The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1639-1644.	0.4	137
95	The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. <i>Journal of Neuro-Oncology</i> , 2013, 112, 467-472.	1.4	137
96	RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1206-1211.	0.4	137
97	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	0.6	137
98	Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 497-504.	0.4	134
99	Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4343-4348.	0.8	132
100	Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394. <i>Journal of Clinical Oncology</i> , 2003, 21, 1485-1491.	0.8	130
101	Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	130
102	Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases. <i>Journal of Clinical Oncology</i> , 2001, 19, 2074-2083.	0.8	126
103	The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 97-102.	1.4	126
104	A nomogram for individualized estimation of survival among patients with brain metastasis. <i>Neuro-Oncology</i> , 2012, 14, 910-918.	0.6	126
105	Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. <i>Brain Pathology</i> , 2008, 18, 360-369.	2.1	125
106	The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 85-96.	1.4	125
107	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. <i>Journal of Neuro-Oncology</i> , 2019, 145, 97-105.	1.4	125
108	Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2188-2194.	0.8	122

#	ARTICLE	IF	CITATIONS
109	The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 927-931.	0.4	121
110	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. <i>Journal of Clinical Oncology</i> , 2016, 34, 1620-1625.	0.8	121
111	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e407-e416.	5.1	119
112	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e396-e406.	5.1	116
113	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , 2015, 17, 992-998.	0.6	116
114	Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. <i>Journal of Neuro-Oncology</i> , 2012, 106, 147-153.	1.4	114
115	Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: How reliable, consistent, and meaningful is the effect?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 135-141.	0.4	110
116	Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4076-4084.	0.8	110
117	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Neuro-Oncology</i> , 2017, 19, now208.	0.6	109
118	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-369.	0.8	109
119	Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. <i>Current Cancer Therapy Reviews</i> , 2011, 7, 319-327.	0.2	108
120	A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. <i>Neuro-Oncology</i> , 2018, 20, 666-673.	0.6	108
121	High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 790-799.	0.4	108
122	Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database. <i>Journal of Clinical Oncology</i> , 2009, 27, 733-739.	0.8	107
123	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126.	0.6	107
124	Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3407-3417.	0.8	107
125	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361.	0.6	105
126	RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. <i>Journal of Clinical Oncology</i> , 2003, 21, 2364-2371.	0.8	101

#	ARTICLE	IF	CITATIONS
127	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2011, 13, 1118-1124.	0.6	100
128	Minimization of small bowel volume within treatment fields utilizing customized "abdominal boards". <i>International Journal of Radiation Oncology Biology Physics</i> , 1990, 19, 469-476.	0.4	99
129	Management of brain metastases. <i>Seminars in Oncology</i> , 2004, 31, 693-701.	0.8	98
130	Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 2048-2049.	13.9	98
131	Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02. <i>Journal of Clinical Oncology</i> , 2014, 32, 535-541.	0.8	97
132	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. <i>Neuro-Oncology</i> , 2012, 14, 1511-1518.	0.6	95
133	Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 300-305.	0.6	94
134	Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. <i>Journal of Neurosurgery</i> , 1995, 82, 530-535.	0.9	93
135	Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 187-195.	0.4	93
136	A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1422-1428.	0.4	92
137	Pseudoprogression after glioma therapy: a comprehensive review. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 389-403.	1.4	92
138	A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 79-86.	0.4	91
139	Prognostic indices for brain metastases " usefulness and challenges. <i>Radiation Oncology</i> , 2009, 4, 10.	1.2	91
140	Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 699-708.	0.4	91
141	American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 310-315.	0.6	91
142	Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. <i>Neuro-Oncology</i> , 2016, 18, 565-574.	0.6	91
143	A Comprehensive Assessment by Tumor Site of Patient Setup Using Daily MVCT Imaging From More Than 3,800 Helical Tomotherapy Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1260-1269.	0.4	90
144	A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. <i>Cancer</i> , 2001, 91, 417-422.	2.0	88

#	ARTICLE	IF	CITATIONS
145	New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. <i>Neuro-Oncology</i> , 2013, 15, 1568-1579.	0.6	88
146	Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. <i>Journal of Neuro-Oncology</i> , 2015, 122, 409-417.	1.4	88
147	Phase II study of paclitaxel in patients with recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2316-2321.	0.8	87
148	Localized 2DJ-resolved H MR spectroscopy of human brain tumorsin vivo. <i>Journal of Magnetic Resonance Imaging</i> , 1996, 6, 453-459.	1.9	87
149	Secondary Analysis of Radiation Therapy Oncology Group study (RTOG) 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma. <i>Journal of Neuro-Oncology</i> , 2005, 74, 201-205.	1.4	86
150	Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 71-78.	0.4	86
151	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 406-413.	0.4	84
152	Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 465-479.	0.8	83
153	Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era. <i>JAMA Oncology</i> , 2017, 3, 784.	3.4	83
154	Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1346-1352.	0.4	81
155	Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 376-381.	0.3	81
156	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 334-343.	0.4	81
157	Reduction in Radiation Dose to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 70-78.	0.6	80
158	Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 4282-4289.	0.8	79
159	Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 27, 963-967.	0.4	78
160	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 362-371.	0.4	78
161	Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Nonâ€“Small-Cell Lung Cancer: The ECOG 3598 Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 616-622.	0.8	75
162	Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 60-65.	2.0	75

#	ARTICLE	IF	CITATIONS
163	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021, 23, 881-893.	0.6	75
164	Pharmacokinetic and Tumor Distribution Characteristics of Temozolomide in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2007, 13, 7401-7406.	3.2	74
165	Tomotherapy and Other Innovative IMRT Delivery Systems. <i>Seminars in Radiation Oncology</i> , 2006, 16, 199-208.	1.0	71
166	Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. <i>Acta Oncologica</i> , 2006, 45, 890-896.	0.8	71
167	Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report. <i>Journal of Clinical Oncology</i> , 1999, 17, 984-984.	0.8	70
168	Neurocognitive and Functional Assessment of Patients With Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 273-279.	0.6	70
169	Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2004, 6, 44-54.	0.6	70
170	Meningeal hemangiopericytoma: defining the role for radiation therapy. <i>Journal of Neuro-Oncology</i> , 1992, 14, 277-87.	1.4	68
171	Development of a Unique Phantom to Assess the Geometric Accuracy of Magnetic Resonance Imaging for Stereotactic Localization. <i>Neurosurgery</i> , 1999, 45, 1423-1431.	0.6	68
172	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. <i>Journal of Neuro-Oncology</i> , 2009, 91, 183-189.	1.4	68
173	Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2850-2857.	0.8	67
174	Targeted Therapy for Brain Metastases: Improving the Therapeutic Ratio. <i>Clinical Cancer Research</i> , 2007, 13, 1675-1683.	3.2	67
175	Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. <i>Cell Cycle</i> , 2016, 15, 2265-2274.	1.3	67
176	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
177	PROOF OF PRINCIPLE OF OCULAR SPARING IN DOGS WITH SINONASAL TUMORS TREATED WITH INTENSITY-MODULATED RADIATION THERAPY. <i>Veterinary Radiology and Ultrasound</i> , 2010, 51, 561-570.	0.4	66
178	Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study. <i>Technology in Cancer Research and Treatment</i> , 2008, 7, 441-447.	0.8	65
179	Current Treatment Strategies for Brain Metastasis and Complications From Therapeutic Techniques. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 398-407.	0.6	65
180	Role of radiation therapy in treating intracranial meningiomas. <i>Neurosurgical Focus</i> , 2007, 23, E4.	1.0	64

#	ARTICLE	IF	CITATIONS
181	Current Therapeutic Paradigms in Glioblastoma. <i>Reviews on Recent Clinical Trials</i> , 2010, 5, 14-27.	0.4	64
182	Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 23, 133-139.	0.4	63
183	Recent advances in managing brain metastasis. <i>F1000Research</i> , 2018, 7, 1772.	0.8	63
184	Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2014, 116, 187-193.	1.4	62
185	Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6647-6656.	0.8	61
186	Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 228-235.	0.4	61
187	Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. <i>Journal of Neuro-Oncology</i> , 2017, 131, 105-115.	1.4	61
188	Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma. <i>Clinical Oncology</i> , 2016, 28, e17-e27.	0.6	60
189	Low-Grade Glioma Radiotherapy Treatment and Trials. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 111-118.	0.8	60
190	Endobronchial irradiation for malignant airway obstruction. <i>International Journal of Radiation Oncology Biology Physics</i> , 1989, 17, 847-851.	0.4	59
191	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. <i>Clinical Cancer Research</i> , 2011, 17, 4872-4881.	3.2	59
192	Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 20, 1053-1060.	0.4	58
193	Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?. <i>Neurological Research</i> , 2005, 27, 387-398.	0.6	58
194	Crimean-Congo haemorrhagic fever in India. <i>Lancet, The</i> , 2011, 378, 372.	6.3	58
195	Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 776-783.	0.8	58
196	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1069-1077.	0.4	58
197	NRG brain tumor specialists consensus guidelines for glioblastoma contouring. <i>Journal of Neuro-Oncology</i> , 2019, 143, 157-166.	1.4	58
198	Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 894-902, 907-15.	0.3	58

#	ARTICLE	IF	CITATIONS
199	Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2004, 6, 33-37.	0.6	57
200	A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. <i>Journal of Neuro-Oncology</i> , 2016, 126, 309-316.	1.4	57
201	Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 644-664.	0.6	56
202	Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3518-3523.	0.8	55
203	Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. <i>Neuro-Oncology</i> , 2004, 6, 96-103.	0.6	55
204	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. <i>Neuro-Oncology</i> , 2009, 11, 167-175.	0.6	55
205	RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 880-884.	0.4	55
206	Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 145-154.	1.1	55
207	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 193-199.	1.4	55
208	Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 25, 309-313.	0.4	54
209	Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy treatment plans for skull-base tumors. <i>Radiotherapy and Oncology</i> , 2006, 78, 313-321.	0.3	54
210	Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 227-233.	1.1	54
211	Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors*. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 27, 1241-1244.	0.4	53
212	Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-00211. <i>Neuro-Oncology</i> , 2006, 8, 47-52.	0.6	53
213	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. <i>Neuro-Oncology</i> , 2020, 22, 94-102.	0.6	53
214	Motexafin-Gadolinium Taken Up In vitro by at Least 90% of Glioblastoma Cell Nuclei. <i>Clinical Cancer Research</i> , 2006, 12, 206-213.	3.2	52
215	Molecular Profiling in Non-Small Cell Lung Cancer: A Step Toward Personalized Medicine. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 481-491.	1.2	52
216	First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M mutant pediatric diffuse intrinsic pontine glioma: a case report. <i>Journal of Neurosurgery: Pediatrics</i> , 2019, 23, 719-725.	0.8	52

#	ARTICLE	IF	CITATIONS
217	RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 1-1.	0.8	52
218	Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon- β for supratentorial glioblastoma: Results of RTOG 9710. International Journal of Radiation Oncology Biology Physics, 2006, 66, 818-824.	0.4	51
219	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. Critical Reviews in Oncology/Hematology, 2018, 126, 13-18.	2.0	51
220	Current radiosurgery practice: results of an astro survey. International Journal of Radiation Oncology Biology Physics, 1994, 28, 523-526.	0.4	50
221	Proton therapy for paediatric CNS tumours "improving treatment-related outcomes. Nature Reviews Neurology, 2016, 12, 334-345.	4.9	50
222	Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review. Neurosurgery, 2019, 84, 19-29.	0.6	50
223	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathologica, 2020, 139, 1071-1088.	3.9	50
224	Monte Carlo and convolution dosimetry for stereotactic radiosurgery. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1027-1035.	0.4	49
225	Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma. Cancer, 2004, 100, 1712-1716.	2.0	49
226	Therapeutic advances for glioblastoma multiforme: Current status and future prospects. Current Oncology Reports, 2007, 9, 66-70.	1.8	49
227	Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. International Journal of Radiation Oncology Biology Physics, 2018, 100, 38-44.	0.4	49
228	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology, 2020, 22, 1359-1367.	0.6	49
229	The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. Journal of Neuro-Oncology, 1996, 30, 1-6.	1.4	48
230	Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy. Clinical Lung Cancer, 2004, 5, 303-306.	1.1	48
231	The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. Journal of Neuro-Oncology, 2010, 96, 115-142.	1.4	48
232	The Evolving Role of Tumor Treating Fields in Managing Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 191-196.	0.6	48
233	Linear Accelerator Radiosurgery for Trigeminal Neuralgia. Neurosurgery, 2005, 57, 1193-1200.	0.6	47
234	Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study. Neuro-Oncology, 2008, 10, 752-758.	0.6	47

#	ARTICLE	IF	CITATIONS
235	A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931). <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1006-1011.	0.4	47
236	Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 662-669.	0.4	47
237	Preservation of Neurocognitive Function (NCF) with Conformal Avoidance of the Hippocampus during Whole-Brain Radiotherapy (HA-WBRT) for Brain Metastases: Preliminary Results of Phase III Trial NRG Oncology CC001. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1607.	0.4	47
238	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. <i>Neuro-Oncology</i> , 2018, 20, 1652-1660.	0.6	47
239	Effect of Endobronchial Radiation Therapy on Malignant Bronchial Obstruction. <i>Chest</i> , 1990, 97, 662-665.	0.4	46
240	A three-dimensional volume visualization package applied to stereotactic radiosurgery treatment planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 21, 491-500.	0.4	46
241	A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study. <i>Neuro-Oncology</i> , 2002, 4, 109-114.	0.6	46
242	Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 852-857.	0.4	46
243	Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 188-193.	0.4	46
244	A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. <i>Neuro-Oncology</i> , 2010, 12, 87-94.	0.6	46
245	Optically guided intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2001, 61, 33-44.	0.3	45
246	Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: Report from the Radiation Therapy Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 318-327.	0.4	45
247	A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. <i>Cancer</i> , 2005, 104, 1968-1974.	2.0	45
248	Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients. <i>Clinical Lung Cancer</i> , 2015, 16, 413-430.	1.1	45
249	The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group. <i>Radiation Oncology</i> , 2008, 3, 32.	1.2	44
250	Brain metastasis and treatment. <i>F1000prime Reports</i> , 2014, 6, 114.	5.9	44
251	Atypical meningioma: Randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 59.	0.3	44
252	Stereotactic Radiosurgery for Treatment of Brain Metastases. <i>Journal of Oncology Practice</i> , 2016, 12, 703-712.	2.5	42

#	ARTICLE	IF	CITATIONS
253	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e33-e42.	5.1	42
254	Helical Tomotherapy as a Means of Delivering Accelerated Partial Breast Irradiation. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 639-646.	0.8	41
255	Increasing Access to Clinical Cancer Trials and Emerging Technologies for Minority Populations: The Native American Project. <i>Journal of Clinical Oncology</i> , 2004, 22, 4452-4455.	0.8	41
256	Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 981-989.	1.1	41
257	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
258	Therapeutic advances in the treatment of brain metastases. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 54-64.	0.3	41
259	Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. <i>Journal of Neuro-Oncology</i> , 2009, 95, 247-257.	1.4	40
260	Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison. <i>Journal of Neuro-Oncology</i> , 2011, 104, 351-356.	1.4	40
261	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 686-693.	3.0	40
262	A Retrospective Review of Nodal Treatment for Vulvar Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993, 16, 38-42.	0.6	39
263	The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A phase III study in a high-risk patient population. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 469-475.	0.4	39
264	A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of the Children's Cancer Group-0952. <i>Neuro-Oncology</i> , 2003, 5, 8-13.	0.6	39
265	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. <i>Neuro-Oncology</i> , 2017, 19, now236.	0.6	39
266	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	0.6	39
267	Neurocognitive sequelae of cancer treatment. <i>Neurology</i> , 2002, 59, 8-10.	1.5	38
268	Current Strategies in Whole-brain Radiation Therapy for Brain Metastases. <i>Neurosurgery</i> , 2005, 57, S4-33-S4-44.	0.6	38
269	Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 831-838.	0.4	38
270	Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 1199-1206.	0.4	37

#	ARTICLE	IF	CITATIONS
271	Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. <i>Cancer</i> , 2005, 104, 1281-1287.	2.0	37
272	Therapeutic management of metastatic brain tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 70-78.	2.0	37
273	Reirradiation for Locoregionally Recurrent Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 70-76.	0.6	37
274	Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells. <i>Oncotarget</i> , 2018, 9, 6883-6896.	0.8	37
275	Glioblastoma: Radiation treatment margins, how small is large enough?. <i>Practical Radiation Oncology</i> , 2016, 6, 298-305.	1.1	36
276	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019, 21, 1100-1117.	0.6	36
277	Radiosurgery for Brain Metastases. <i>Neurosurgery Clinics of North America</i> , 1999, 10, 337-350.	0.8	35
278	Early toxicity predicts long-term survival in high-grade glioma. <i>British Journal of Cancer</i> , 2011, 104, 1365-1371.	2.9	35
279	Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2000-2000.	0.8	35
280	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	0.6	35
281	On the Use of Hyperpolarized Helium MRI for Conformal Avoidance Lung Radiotherapy. <i>Medical Dosimetry</i> , 2010, 35, 297-303.	0.4	34
282	Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 1993, 15, 57-66.	1.4	33
283	Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. <i>Journal of Neuro-Oncology</i> , 2008, 89, 313-337.	1.4	33
284	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. <i>Neuro-Oncology</i> , 2018, 20, 966-974.	0.6	33
285	Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S78.	0.4	33
286	Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 720-725.	0.4	33
287	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> . 2022. 114. 60-74.	0.4	33
288	The physical, biologic, and clinical basis of radiosurgery. <i>Current Problems in Cancer</i> , 1995, 19, 270-328.	1.0	32

#	ARTICLE	IF	CITATIONS
289	A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). <i>Journal of Neuro-Oncology</i> , 2000, 47, 145-152.	1.4	32
290	Gentlemen (and Ladies), Choose your Weapons: Gamma Knife vs. Linear Accelerator Radiosurgery. <i>Technology in Cancer Research and Treatment</i> , 2003, 2, 79-85.	0.8	32
291	The Impact of Mid-Treatment MRI on Defining Boost Volumes in the Radiation Treatment of Glioblastoma Multiforme. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 303-307.	0.8	32
292	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 99-111.	2.0	32
293	Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 893-899.	0.4	32
294	Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 207-216.	1.4	32
295	Stereotactic Radiosurgery for Glioblastoma. <i>Cureus</i> , 2015, 7, e413.	0.2	32
296	Radiation induced thyroid neoplasms 1920 to 1987: A vanishing problem?. <i>International Journal of Radiation Oncology Biology Physics</i> , 1989, 16, 1471-1475.	0.4	31
297	O 6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. <i>Neuro-Oncology</i> , 2004, 6, 28-32.	0.6	31
298	Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 204-213.	0.4	31
299	Megavoltage Computed Tomography. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 617-623.	0.6	31
300	The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 149-158.	0.8	31
301	CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. <i>Journal of Neuro-Oncology</i> , 2016, 126, 327-336.	1.4	31
302	NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2009-2009.	0.8	31
303	Motexafin gadolinium in the treatment of brain metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 351-359.	0.9	30
304	Combined Radio- and Chemotherapy of Brain Tumours in Adult Patients. <i>Clinical Oncology</i> , 2009, 21, 515-524.	0.6	30
305	The Dandelion Effect: Treat the Whole Lawn or Weed Selectively?. <i>Journal of Clinical Oncology</i> , 2011, 29, 121-124.	0.8	30
306	Magnetic resonance angiography: a three-dimensional database for assessing arteriovenous malformations. <i>Journal of Neurosurgery</i> , 1993, 79, 289-293.	0.9	29

#	ARTICLE	IF	CITATIONS
307	Walking Forward: The South Dakota Native American Project. <i>Journal of Cancer Education</i> , 2005, 20, 65-70.	0.6	29
308	Helical Tomotherapy: Image Guidance and Adaptive Dose Guidance. , 2007, 40, 162-178.		28
309	A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1422-1427.	0.4	28
310	A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 820-828.	0.4	28
311	Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium. <i>Neuro-Oncology</i> , 2008, 10, 631-642.	0.6	27
312	Real-Time Pretreatment Review Limits Unacceptable Deviations on a Cooperative Group Radiation Therapy Technique Trial: Quality Assurance Results of RTOG 0933. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 564-570.	0.4	27
313	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. <i>Journal of Neuro-Oncology</i> , 2015, 124, 413-420.	1.4	27
314	Consensus statement on stereotactic radiosurgery quality improvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 28, 527-530.	0.4	26
315	Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiosurgery for patients with single intracranial metastases. <i>Journal of Neuro-Oncology</i> , 2012, 108, 141-146.	1.4	26
316	The role of radiation in treating glioblastoma: here to stay. <i>Journal of Neuro-Oncology</i> , 2017, 134, 479-485.	1.4	26
317	Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 687-693.	0.6	26
318	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 39-45.	0.9	26
319	Cavernous sinus cranial neuropathies: is there a dose-response relationship following radiosurgery?. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 27, 477-480.	0.4	25
320	Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2000, 2, 48-52.	1.1	25
321	Fractionated Stereotactic Radiotherapy: A Short Review. <i>Technology in Cancer Research and Treatment</i> , 2002, 1, 153-172.	0.8	25
322	Breathing-Synchronized Delivery: A Potential Four-Dimensional Tomotherapy Treatment Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1572-1578.	0.4	25
323	Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. <i>Acta Oncologica</i> , 2011, 50, 772-776.	0.8	25
324	NRG/TOG 1122: A phase 2, double-blind, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. <i>Cancer</i> , 2020, 126, 2821-2828.	2.0	25

#	ARTICLE	IF	CITATIONS
325	Stereotactic Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 143-146.	0.6	25
326	Advances in Radiation Therapy for Brain Tumors. Neurologic Clinics, 2007, 25, 1005-1033.	0.8	24
327	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Journal of Neuro-Oncology, 2019, 144, 205-210.	1.4	24
328	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiation Oncology, 2019, 14, 33.	1.2	24
329	Craniospinal treatment with the patient supine. Medical Dosimetry, 2003, 28, 35-38.	0.4	23
330	Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Review of Anticancer Therapy, 2007, 7, 785-794.	1.1	23
331	Opportunities for clinical research in meningioma. Journal of Neuro-Oncology, 2010, 99, 417-422.	1.4	23
332	The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. Neuro-Oncology, 2015, 17, 919-923.	0.6	23
333	Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Archives of Virology, 2016, 161, 3161-3169.	0.9	23
334	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	0.6	23
335	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	0.8	23
336	Thoracic volume radiation sparing following endobronchial brachytherapy: A quantitative analysis. International Journal of Radiation Oncology Biology Physics, 1993, 25, 703-707.	0.4	22
337	Radiation Therapy for Leptomeningeal Cancer. , 2005, 125, 147-158.		22
338	Fractionated radiotherapy for intracranial meningiomas. Journal of Neuro-Oncology, 2010, 99, 349-356.	1.4	22
339	A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. Journal of Neuro-Oncology, 2017, 133, 589-594.	1.4	22
340	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 845-853.	0.4	22
341	Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. Journal of Neuro-Oncology, 2018, 140, 421-426.	1.4	22
342	Strategies for preservation of memory function in patients with brain metastases. Chinese Clinical Oncology, 2015, 4, 24.	0.4	22

#	ARTICLE	IF	CITATIONS
343	Models Support Prophylactic Cranial Irradiation. <i>Journal of Clinical Oncology</i> , 2006, 24, 3524-3526.	0.8	21
344	Dose Coverage Beyond the Gross Tumor Volume for Various Stereotactic Body Radiotherapy Planning Techniques Reporting Similar Control Rates for Stage I Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1597-1603.	0.4	21
345	It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology. <i>Journal of Clinical Oncology</i> , 2011, 29, 3211-3213.	0.8	21
346	It Is Time to Reevaluate the Management of Patients With Brain Metastases. <i>Neurosurgery</i> , 2014, 75, 1-9.	0.6	21
347	Brain Metastasis and Response to Ado-Trastuzumab Emtansine: A Case Report and Literature Review. <i>Clinical Breast Cancer</i> , 2015, 15, e163-e166.	1.1	21
348	Low Levels of Acute Toxicity Associated With Proton Therapy for Low-Grade Glioma: A Proton Collaborative Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E135.	0.4	21
349	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2017, 134, 331-338.	1.4	21
350	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. <i>Journal of Neuro-Oncology</i> , 2018, 136, 79-86.	1.4	21
351	A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424. <i>Journal of Clinical Oncology</i> , 2013, 31, 2008-2008.	0.8	21
352	Dimension in defining tumor response. <i>Journal of Clinical Oncology</i> , 1998, 16, 1234-1234.	0.8	20
353	Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. <i>Seminars in Radiation Oncology</i> , 2003, 13, 3-12.	1.0	20
354	Proton radiotherapy for gynecologic neoplasms. <i>Acta Oncologica</i> , 2016, 55, 1257-1265.	0.8	20
355	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	0.6	20
356	CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 166, 101-109.	0.3	20
357	Temozolomide-induced severe myelosuppression. <i>Anti-Cancer Drugs</i> , 2011, 22, 104-110.	0.7	19
358	The Changing Role of Whole-Brain Radiotherapy. <i>JAMA Oncology</i> , 2017, 3, 1021.	3.4	19
359	Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. <i>Frontiers in Oncology</i> , 2020, 10, 254.	1.3	19
360	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 691-703.	1.4	18

#	ARTICLE	IF	CITATIONS
361	Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1107-1115.	0.4	18
362	Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: A phase III combined modality study. <i>Pediatric Blood and Cancer</i> , 2005, 45, 676-682.	0.8	18
363	The impact of linac output variations on dose distributions in helical tomotherapy. <i>Physics in Medicine and Biology</i> , 2008, 53, 417-430.	1.6	18
364	Commissioning and Quality Assurance of RapidArc Radiotherapy Delivery System: In Regard to Ling et al. (<i>Int J Radiat Oncol Biol Phys</i> 2008;72;575-581): Absence of Data Does Not Constitute Proof; The Proof is in Tasting the Pudding. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 4-6.	0.4	18
365	Novel insights into the management of brain metastases. <i>Current Opinion in Neurology</i> , 2010, 23, 556-562.	1.8	18
366	Current practices of driving restriction implementation for patients with brain tumors. <i>Journal of Neuro-Oncology</i> , 2011, 103, 641-647.	1.4	18
367	Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 411-415.	0.3	18
368	Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 221-230.	1.1	18
369	Updates in the management of intradural spinal cord tumors: a radiation oncology focus. <i>Neuro-Oncology</i> , 2019, 21, 707-718.	0.6	18
370	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. <i>Neuro-Oncology</i> , 2019, 21, vi137-vi137.	0.6	18
371	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	3.2	18
372	Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2004-2004.	0.8	18
373	Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA2010-LBA2010.	0.8	18
374	Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT + TMZ vs RT + nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2016-2016.	0.8	18
375	Management of solitary and multiple brain metastases from breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 87-93.	0.1	18
376	Treatment of Wilms's Tumour. <i>Drugs</i> , 1991, 42, 766-780.	4.9	17
377	Linear accelerator configurations for radiosurgery. <i>Seminars in Radiation Oncology</i> , 1995, 5, 203-212.	1.0	17
378	Trastuzumab for Breast Cancer-Related Carcinomatous Meningitis. <i>Clinical Breast Cancer</i> , 2002, 2, 316.	1.1	17

#	ARTICLE	IF	CITATIONS
379	Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1122-1126.	0.4	17
380	Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. <i>Current Problems in Cancer</i> , 2004, 28, 7-40.	1.0	17
381	A Comparison of Helical Tomotherapy to Circular Collimator-Based Linear-Accelerator Radiosurgery for the Treatment of Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 388-394.	0.6	17
382	Radiation-induced brain damage, impact of Michael Robbins's work and the need for predictive biomarkers. <i>International Journal of Radiation Biology</i> , 2014, 90, 742-752.	1.0	17
383	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 75-81.	1.8	17
384	Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 365-374.	1.0	17
385	Preradiation Chemotherapy for Adult High-risk Medulloblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 588-594.	0.6	17
386	Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. <i>Advances in Radiation Oncology</i> , 2019, 4, 579-586.	0.6	17
387	Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of 6 brain metastases: a multi-institutional phase II trial. <i>Journal of Neuro-Oncology</i> , 2011, 105, 301-308.	1.4	16
388	Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 480-485.	0.6	16
389	Strategies to Prevent Brain Metastasis in High-Risk Non-Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation. <i>Clinical Lung Cancer</i> , 2014, 15, 433-440.	1.1	16
390	Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure. <i>Radiation Research</i> , 2020, 194, 1.	0.7	16
391	Assessment of patient-independent intrinsic error for a noninvasive frame for fractionated stereotactic radiotherapy. <i>International Journal of Cancer</i> , 2001, 96, 320-325.	2.3	15
392	Combined modality treatment for central nervous system malignancies. <i>Seminars in Oncology</i> , 2003, 30, 11-22.	0.8	15
393	Motexafin gadolinium: a novel radiosensitizer for brain tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2171-2180.	0.9	15
394	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. <i>Medical Hypotheses</i> , 2011, 76, 410-413.	0.8	15
395	Role of isocitrate dehydrogenase in glioma. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1399-1409.	1.4	15
396	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). <i>Journal of Neuro-Oncology</i> , 2013, 111, 33-39.	1.4	15

#	ARTICLE	IF	CITATIONS
397	Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. <i>Neuro-Oncology</i> , 2015, 17, 999-1006.	0.6	15
398	What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases?. <i>Journal of Neuro-Oncology</i> , 2016, 127, 303-311.	1.4	15
399	Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab010.	0.4	15
400	Helical Tomotherapy as a Means of Delivering Scalp-sparing Whole Brain Radiation Therapy. <i>Technology in Cancer Research and Treatment</i> , 2005, 4, 661-662.	0.8	14
401	Brain metastases. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 85-90.	0.5	14
402	Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 655-667.	1.1	14
403	Whole-Brain Radiotherapy and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e99-e104.	1.8	14
404	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. <i>Cancers</i> , 2021, 13, 3682.	1.7	14
405	Treatment of Probable Subclinical Liver Metastases and Gross Pancreatic Carcinoma with Hepatic Artery 5-Fluorouracil Infusion and Radiation Therapy. <i>Acta OncolÃ³gica</i> , 1988, 27, 377-381.	0.8	13
406	Recurrent Malignant Gliomas Treated with Radiosurgery. <i>Journal of Radiosurgery</i> , 1999, 2, 119-125.	0.1	13
407	Title is missing!. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 273-279.	0.6	13
408	Potential for Radiation Therapy Technology Innovations to Permit Dose Escalation for Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, 107-113.	1.1	13
409	Radiation Techniques in Neuro-Oncology. <i>Neurotherapeutics</i> , 2009, 6, 487-499.	2.1	13
410	Stereotactic Body Radiation Therapy in Nonâ€“Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 432-441.	0.6	13
411	Prophylactic cranial irradiation: recent outcomes and innovations. <i>CNS Oncology</i> , 2014, 3, 219-230.	1.2	13
412	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stageÃ disease. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 515-524.	1.0	13
413	What is the evidence for the clinical value of SBRT in cancer of the cervix?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018, 23, 574-579.	0.3	13
414	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. <i>Translational Research</i> , 2019, 208, 63-72.	2.2	13

#	ARTICLE	IF	CITATIONS
415	Effectiveness of Radiofrequency Ablation in the Treatment of Painful Osseous Metastases: A Correlation Meta-Analysis with Machine Learning Cluster Identification. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1753-1762.	0.2	13
416	Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 32-39.	0.8	13
417	In regard to Dr. Souhami et al. (<i>Int J Radiat Oncol Biol Phys</i> 2004;60:853-860). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 614-615.	0.4	12
418	Resection versus radiosurgery for patients with brain metastases. <i>Future Oncology</i> , 2007, 3, 95-102.	1.1	12
419	On the Estimation of the Location of the Hippocampus in the Context of Hippocampal Avoidance Whole Brain Radiotherapy Treatment Planning. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 425-432.	0.8	12
420	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 341-349.	1.4	12
421	Free Breathing versus Breath-Hold Scanning Beam Proton Therapy and Cardiac Sparing in Breast Cancer. <i>International Journal of Particle Therapy</i> , 2016, 3, 407-413.	0.9	12
422	The Status of Stereotactic Radiosurgery for Cerebral Metastases in 1998. <i>Journal of Radiosurgery</i> , 1998, 1, 17-30.	0.1	11
423	Radiotherapy for brain tumors. <i>Current Oncology Reports</i> , 2000, 2, 438-444.	1.8	11
424	Clinical ramifications of "genomic staging" of low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 129, 195-199.	1.4	11
425	ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi20-vi20.	0.6	11
426	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Journal of Neuro-Oncology</i> , 2021, 155, 363-372.	1.4	11
427	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. <i>JCO Oncology Practice</i> , 2022, 18, e780-e785.	1.4	11
428	90Y $\dot{\Lambda}$ B72.3 Against pancreatic cancer: Dosimetric and biological analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1990, 19, 627-631.	0.4	10
429	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. <i>Lancet Oncology</i> , The, 2018, 19, e366.	5.1	10
430	Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 878-886.	0.4	10
431	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). <i>Neuro-Oncology</i> , 2021, 23, 1125-1138.	0.6	10
432	Systematic evaluation and plan quality assessment of the Leksell $\dot{\Lambda}$ gamma knife $\dot{\Lambda}$ lightning dose optimizer. <i>Medical Dosimetry</i> , 2021, , .	0.4	10

#	ARTICLE	IF	CITATIONS
433	Impact of molecular profiling on clinical trial design for glioblastoma. <i>Current Oncology Reports</i> , 2007, 9, 71-79.	1.8	9
434	In Regard to Sperduto et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 809-810.	0.4	9
435	Chemoradiation for Definitive, Preoperative, or Postoperative Therapy of Locally Advanced Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 222-230.	1.0	9
436	Three-dimensional conformal radiotherapy for lung cancer: Promises and pitfalls. <i>Current Oncology Reports</i> , 2002, 4, 347-353.	1.8	8
437	Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol: In regard to Souhami et al. (<i>Int J Radiat Oncol Biol Phys</i> 2004;60:853â€“860). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 296-297.	0.4	8
438	Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced Non-Small Cell Lung Cancer: Combined Modality Treatment?. <i>Seminars in Oncology</i> , 2005, 32, 25-34.	0.8	8
439	Combined Modality Approaches in the Management of Adult Glioblastoma. <i>Frontiers in Oncology</i> , 2011, 1, 36.	1.3	8
440	Phase I Safety and Pharmacokinetic (PK) Study of Veliparib in Combination With Whole Brain Radiation Therapy (WBRT) in Patients (pts) With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S269-S270.	0.4	8
441	Potential of glyburide to reduce intracerebral edema in brain metastases. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 379-388.	1.4	8
442	International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1102-1106.	0.4	8
443	Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. <i>Anticancer Research</i> , 2019, 39, 2911-2918.	0.5	8
444	Genetic landscape of extreme responders with anaplastic oligodendroglioma. <i>Oncotarget</i> , 2017, 8, 35523-35531.	0.8	8
445	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. <i>Scientific Reports</i> , 2022, 12, 4567.	1.6	8
446	Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 164-165.	0.4	7
447	Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2922-2922.	0.8	7
448	Helical tomotherapy as a means of administering total or partial scalp irradiation: In regards to Bedford et al. (<i>Int J Radiat Oncol Biol Phys</i> 2005;62:1549â€“1558). <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1288-1289.	0.4	7
449	A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 175-179.	1.1	7
450	Integrated phase II/III clinical trials in oncology: A case study. <i>Clinical Trials</i> , 2012, 9, 741-747.	0.7	7

#	ARTICLE	IF	CITATIONS
451	Brain Metastases Research 1990â€“2010: Pattern of Citation and Systematic Review of Highly Cited Articles. <i>Scientific World Journal</i> , The, 2012, 2012, 1-9.	0.8	7
452	AT-13 * R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRIStINE (PCV) IN LOW-GRADE GLIOMA: RESULTS BY HISTOLOGIC TYPE. <i>Neuro-Oncology</i> , 2014, 16, v11-v11.	0.6	7
453	Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis. <i>Neuro-Oncology</i> , 2018, 20, 2-3.	0.6	7
454	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. <i>Neurosurgery</i> , 2019, 84, 66-76.	0.6	7
455	Case report of visual biofeedback-driven, magnetic resonance-guided single-fraction SABR in breath hold for early stage nonâ€“small-cell lung cancer. <i>Medical Dosimetry</i> , 2021, 46, 247-252.	0.4	7
456	Novel Radiation Approaches. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 211-223.	0.8	7
457	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. <i>Radiotherapy and Oncology</i> , 2021, 159, 17-20.	0.3	7
458	Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 2021-2021.	0.8	7
459	Anteriorly Oriented Beam Arrangements with Daily in Vivo Range Verification for Proton Therapy of Prostate Cancer: Rectal Toxicity Rates. <i>International Journal of Particle Therapy</i> , 2016, 2, 509-517.	0.9	7
460	Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy. , 2013, 4, 59.		7
461	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. <i>Discover Oncology</i> , 2021, 12, 48.	0.8	7
462	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 780379.	1.3	7
463	Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. <i>Cancers</i> , 2022, 14, 2020.	1.7	7
464	A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. <i>Investigational New Drugs</i> , 2003, 21, 429-433.	1.2	6
465	A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. <i>Lung Cancer</i> , 2004, 44, 111-119.	0.9	6
466	Temozolomide as Prophylaxis for Brain Metastasis in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 732-733.	0.5	6
467	Recent Updates in the Treatment of Glioblastoma: Introduction. <i>Seminars in Oncology</i> , 2014, 41, S1-S3.	0.8	6
468	Identification of Patients Who Benefit From Bevacizumab in High-Grade Gliomaâ€“An Easy Question Turned Difficult: Treat the Scan or the Patient?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1281-1282.	0.8	6

#	ARTICLE	IF	CITATIONS
469	The Complexity of Managing Large Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2019, 104, 483-484.	0.4	6
470	Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. Cancers, 2021, 13, 2186.	1.7	6
471	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. Neuro-Oncology Practice, 2021, 8, 662-673.	1.0	6
472	Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. JCO Precision Oncology, 2021, 5, 1397-1407.	1.5	6
473	SU-F-R-04: Radiomics for Survival Prediction in Glioblastoma (GBM). Medical Physics, 2016, 43, 3373-3373.	1.6	6
474	Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA).. Journal of Clinical Oncology, 2015, 33, 2002-2002.	0.8	6
475	Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.. Journal of Clinical Oncology, 2019, 37, 2002-2002.	0.8	6
476	Dose-Escalated Magnetic Resonance Imageâ€“Guided Abdominopelvic Reirradiation With Continuous Intrafraction Visualization, Soft Tissue Tracking, and Automatic Beam Gating. Advances in Radiation Oncology, 2022, 7, 100840.	0.6	6
477	A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro-Oncology, 2002, 4, 109-14.	0.6	6
478	Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide. Clinical Advances in Hematology and Oncology, 2003, 1, 231-6.	0.3	6
479	Dedicated isotropic 3-D T1 SPACE sequence imaging for radiosurgery planning improves brain metastases detection and reduces the risk of intracranial relapse. Radiotherapy and Oncology, 2022, 173, 84-92.	0.3	6
480	Stereotactic Radiosurgery for Glioblastoma multiforme. Stereotactic and Functional Neurosurgery, 1994, 63, 233-240.	0.8	5
481	Radiation Oncology Advances: An Introduction. Cancer Treatment and Research, 2008, 139, 1-4.	0.2	5
482	Radiographic Pneumonitis Patterns and Low Pulmonary Toxicity After Helical Tomotherapy. American Journal of Roentgenology, 2010, 194, W459-W459.	1.0	5
483	Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report. Tumori, 2013, 99, e38-e42.	0.6	5
484	An Independently Validated Nomogram for Individualized Estimation of Survival Among Patients With Newly Diagnosed Glioblastoma: NRG Oncology/RTOG 0525 and 0825. International Journal of Radiation Oncology Biology Physics, 2016, 96, S92.	0.4	5
485	The association between BMI and BSAâ€“temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neuro-Oncology Practice, 2019, 6, 473-478.	1.0	5
486	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neuro-Oncology Advances, 2020, 2, vdaa124.	0.4	5

#	ARTICLE	IF	CITATIONS
487	Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 47-53.	0.8	5
488	Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report. <i>Medical Dosimetry</i> , 2021, 46, 384-388.	0.4	5
489	NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2053-2053.	0.8	5
490	A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 155, 297-306.	1.4	5
491	Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab166.	0.4	5
492	Hospitalization rates from radiotherapy complications in the United States. <i>Scientific Reports</i> , 2022, 12, 4371.	1.6	5
493	Zero Setup Margin Mask versus Frame Immobilization during Gamma Knife® Iconâ,ç Stereotactic Radiosurgery for Brain Metastases. <i>Cancers</i> , 2022, 14, 3392.	1.7	5
494	Adult Wilms' Tumor: Role of Combined Modality Treatment. <i>Acta OncolÃ³gica</i> , 1989, 28, 647-650.	0.8	4
495	Thorotrast-associated Oropharyngeal Hemorrhage: Treatment by Means of Carotid Occlusion with Use of Flow Arrest and Fibered Coils. <i>Journal of Vascular and Interventional Radiology</i> , 1996, 7, 709-712.	0.2	4
496	Late Recurrence of a Primitive Neuro-Ectodermal Tumor. <i>Oncology</i> , 2001, 61, 189-191.	0.9	4
497	Multiple daily fractionation radiotherapy schedules in lung cancer. <i>Current Oncology Reports</i> , 2001, 3, 179-184.	1.8	4
498	Pineal Sarcoma. <i>Acta Neurochirurgica</i> , 2002, 144, 89-92.	0.9	4
499	What is the appropriate primary end point for clinical trials for patients with brain metastases? In Response to Drs. Burri and Asher. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 1394.	0.4	4
500	Breath-Hold Intensity Modulated Proton Therapy (BH-IMPT) for Lung SBRT: Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S142.	0.4	4
501	High prevalence of hepatitis B non-immunity in paediatric non-alcoholic fatty liver disease patients. <i>Digestive and Liver Disease</i> , 2014, 46, 760-761.	0.4	4
502	ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRIStINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2015, 17, v3.1-v3.	0.6	4
503	Cost-Effectiveness of Prophylactic Cranial Irradiation With Hippocampal Avoidance in Limited Stage Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, S92.	0.4	4
504	Significant Preservation of Neurocognitive Function (NCF) and Patient-Reported Symptoms with Hippocampal Avoidance (HA) during Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Final Results of Nrg Oncology CC001. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S12-S13.	0.4	4

#	ARTICLE	IF	CITATIONS
505	Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 964.	0.7	4
506	Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. <i>Current Oncology</i> , 2021, 28, 1537-1543.	0.9	4
507	Abstract 736: RTOG 0320: A phase III trial comparing whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone versus WBRT with temozolomide (TMZ) or erlotinib for non-small cell lung cancer (NSCLC) and 1-3 brain metastases. <i>Cancer Research</i> , 2012, 72, 736-736.	0.4	4
508	Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology's RTOG 0614. <i>Journal of Clinical Oncology</i> , 2018, 36, 2065-2065.	0.8	4
509	Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA). <i>Journal of Clinical Oncology</i> , 2019, 37, 1079-1079.	0.8	4
510	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 75-81.	1.8	4
511	Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402. <i>Journal of Clinical Oncology</i> , 2016, 34, 2054-2054.	0.8	4
512	An overview of modern proton therapy. <i>Chinese Clinical Oncology</i> , 2016, 5, 48-48.	0.4	4
513	Comparison of Methods for Response Analysis of Central Nervous System Neoplasms. <i>Journal of Radiosurgery</i> , 1999, 2, 153-161.	0.1	3
514	Accelerated hypofractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 299-300.	0.4	3
515	Strategies for enhanced radiation delivery in patients with lung cancer. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 103-113.	2.4	3
516	1014. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S136-S137.	0.4	3
517	Whole Brain Radiation Therapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost With Helical Tomotherapy: A Planning Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S674-S675.	0.4	3
518	Gangliogliomas—what is the appropriate management strategy?. <i>Nature Reviews Neurology</i> , 2010, 6, 190-191.	4.9	3
519	In response to "The distribution of brain metastases in the perihippocampal region (Regarding Gondi et al)". <i>Journal of Clinical Oncology</i> , 2011, 29, 1033-1034.	0.3	3
520	RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S128-S129.	0.4	3
521	In Regard to Yamamoto et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 875-876.	0.4	3
522	Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). <i>Biomarker Research</i> , 2013, 1, 29.	2.8	3

#	ARTICLE	IF	CITATIONS
523	ATCT-08 THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG. <i>Neuro-Oncology</i> , 2015, 17, v2.4-v2.	0.6	3
524	ATCT-27 NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v7.3-v7.	0.6	3
525	In Regard to Badiyan et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 453-454.	0.4	3
526	Pathologic deposition of non-amyloid immunoglobulin in the brain leading to mass effect and neurological deficits. <i>Journal of Clinical Neuroscience</i> , 2016, 30, 143-145.	0.8	3
527	Role of Radiosensitizers in Radiation Treatment of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 31, 102-115.	1.3	3
528	Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 59-60.	0.4	3
529	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	0.6	3
530	Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2019, 30, ii70-ii71.	0.6	3
531	Early imaging marker of progressing glioblastoma: a window of opportunity. <i>Journal of Neuro-Oncology</i> , 2020, 148, 629-640.	1.4	3
532	Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80 cc): Feasibility and Dosimetric Outcomes. <i>Advances in Radiation Oncology</i> , 2021, 6, 100651.	0.6	3
533	Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery. <i>Neuro-Oncology Practice</i> , 2021, 8, 674-683.	1.0	3
534	METIS: A phase 3 study of radiosurgery with TTF fields for 1-10 brain metastases from NSCLC. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9106-TPS9106.	0.8	3
535	Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3005-3005.	0.8	3
536	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. <i>Scientific Reports</i> , 2021, 11, 22152.	1.6	3
537	Relationship between insurance status and interhospital transfers among cancer patients in the United States. <i>BMC Cancer</i> , 2022, 22, 121.	1.1	3
538	Gamma Knife Radiosurgery for 5 to 10 Brain Metastases: May Not Be Reasonable as Sole Upfront Treatment. <i>Oncology</i> , 2016, 30, 314, 316-7.	0.4	3
539	Brain metastases. , 2008, , 170-186.		2
540	In reply to Dr. Kondziolka et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 615-616.	0.4	2

#	ARTICLE	IF	CITATIONS
541	Dosimetric Evaluation of Helical IMRT, Traditional IMRT and 3-D Conformal Radiation for Inoperable Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S632-S633.	0.4	2
542	Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S129-S130.	0.4	2
543	Reply to M.C. Chamberlain et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 3316-3317.	0.8	2
544	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014, 32, 1634-1635.	0.8	2
545	RTRB-05DEFINING THE ROLE OF PROPHYLACTIC CRANIAL IRRADIATION IN NSCLC: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE WORLD'S LITERATURE. <i>Neuro-Oncology</i> , 2015, 17, v196.1-v196.	0.6	2
546	ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA. <i>Neuro-Oncology</i> , 2015, 17, v6.2-v6.	0.6	2
547	Should we irradiate a brain tumor in a patient with parkinsonism? A case report and literature review. <i>Practical Radiation Oncology</i> , 2015, 5, e327-e335.	1.1	2
548	Radiomics for Survival Analysis and Prediction in Glioblastoma (GBM) – A Preliminary Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E106-E107.	0.4	2
549	Interobserver Variability in Atlas-Based, Manual Segmentation of the Hippocampus in Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E130.	0.4	2
550	Principles of radiation therapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 131-147.	1.0	2
551	Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3107-3108.	0.8	2
552	Prognostic Factors in Patients with Renal Cell Carcinoma and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S169-S170.	0.4	2
553	Inpatient Palliative Care Use Among Critically Ill Brain Metastasis Patients in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 806-812.	0.6	2
554	A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1529-1535.	1.0	2
555	Stereotactic Irradiation. , 2012, , 331-343.		2
556	Intratumoral activity of ONC201 in adult recurrent glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14034-e14034.	0.8	2
557	Prognostic value of H-MLH1 after adjusting for RPA class in GBM patients. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 1182-1191.	0.9	2
558	Novel radiosensitizers for tumors of the central nervous system. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 1284-91.	2.3	2

#	ARTICLE	IF	CITATIONS
559	Is proton beam therapy better than standard radiation therapy? The available evidence points to benefits of proton beam therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 861-4.	0.3	2
560	Using intensity-modulated radiotherapy to spare the kidney in a patient with seminoma and a solitary kidney: a case report. <i>Tumori</i> , 2013, 99, e38-42.	0.6	2
561	Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results. <i>Cancers</i> , 2022, 14, 2946.	1.7	2
562	Endobronchial brachytherapy: Wither prescription point. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 23, 251.	0.4	1
563	LINAC-based radiosurgery in the treatment of trigeminal neuralgia: a preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 303-304.	0.4	1
564	How Can Tumor Effect and Normal Tissue Effect Be Balanced in Stereotactic Body Radiotherapy. , 2006, 6, 86-97.		1
565	In response to Dr. Peñagaricano. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1274-1275.	0.4	1
566	1110. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S193-S194.	0.4	1
567	A Prospective Study Comparing CT-Based to PET/CT-based Radiation Treatment Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S68-S69.	0.4	1
568	Interim Results of a Phase I Risk-Stratified Dose Escalation Study using Hypofractionated Helical Tomotherapy for Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S107-S108.	0.4	1
569	Simultaneously Integrated Boost to Multiple Brain Metastases during Whole Brain Radiation Therapy-Hippocampal Avoidance. <i>Radiosurgery</i> , 2010, , 247-257.	0.1	1
570	Predicting Neurocognitive Function (NCF) Impairment following Fractionated Stereotactic Radiotherapy (FSRT) for Benign or Low-Grade Adult Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S285-S286.	0.4	1
571	In Response to Dr. Knisely and Colleagues. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 958.	0.4	1
572	Predictive Factors for Brain Metastases and Relapse and Prognostic Factors for Survival in Stage III-IV Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S525.	0.4	1
573	Credentialing in Hippocampal (HC) Sparing Techniques for RTOG 0933: Quality Assurance (QA) Report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S576.	0.4	1
574	Proton Beam Therapy Basics. <i>Journal of the American College of Radiology</i> , 2015, 12, 1204-1206.	0.9	1
575	Novel Proton Beam Arrangements for Prostate Cancer Using In Vivo Range Verification May Significantly Reduce the Risk of High Grade Rectal Toxicities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, E559-E560.	0.4	1
576	ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v12.2-v12.	0.6	1

#	ARTICLE	IF	CITATIONS
577	Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases. Neuro-Oncology Practice, 2015, 2, 57-61.	1.0	1
578	ATCT-12 RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA). Neuro-Oncology, 2015, 17, v3.4-v3.	0.6	1
579	Proton Therapy in the USA From 2012 to 2014â€”Increasing Treatment of Pediatric, Lung, Head and Neck, Gastrointestinal, and Breast Cancers, But No Increase in Prostate Cancer Treatments: A Study From the National Association for Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, S136-S137.	0.4	1
580	The Effect of Gene Mutations on Survival in Patients With Melanoma Following the Development of Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 96, S178.	0.4	1
581	Treatment Responses and Survival in IDH1-Mutant Grade II and III Gliomas in NRG Oncology/RTOG 9802 and 9813. International Journal of Radiation Oncology Biology Physics, 2016, 94, 6.	0.4	1
582	Basic principles of brain tumor radiotherapy. , 2019, , 245-262.		1
583	WHO II and III Gliomas. , 2019, , 217-236.		1
584	Effect of Postoperative Radiation Therapy Timing on Survival in Pediatric and Young Adult Ependymoma. Advances in Radiation Oncology, 2021, 6, 100691.	0.6	1
585	Radiation for Brain Metastases. Cancer Treatment and Research, 2007, 136, 91-115.	0.2	1
586	RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from HER2-positive breast cancerâ€”A collaborative study of RTOG and KROC (NCT01622868).. Journal of Clinical Oncology, 2014, 32, TPS664-TPS664.	0.8	1
587	Comprehensive mutation analysis in NRG Oncology/RTOG 9802: A phase III study of RT vs RT + PCV in high-risk low-grade gliomas (LGGs).. Journal of Clinical Oncology, 2016, 34, 2017-2017.	0.8	1
588	Barriers to accrual and enrollment in brain tumor trials.. Journal of Clinical Oncology, 2019, 37, 2024-2024.	0.8	1
589	Combined Chemoradiotherapy Advances. Cancer Treatment and Research, 2008, , 277-301.	0.2	1
590	A Comprehensive Analysis of a Prospective Multidisciplinary Peer Review Process Before Radiation Therapy Simulation. Practical Radiation Oncology, 2020, 11, e366-e375.	1.1	1
591	Brain metastases: the changing landscape. Oncology, 2015, 29, 257-60.	0.4	1
592	Evaluation of a prospective radiation oncology departmental team review process using standardized simulation directives. Radiotherapy and Oncology, 2021, , .	0.3	1
593	RONC-13. Change in hippocampus volume as a function of radiation dose: Results from a prospective trial with standardized imaging and morphometric evaluation. Neuro-Oncology, 2022, 24, i179-i179.	0.6	1
594	Endobronchial irradiation: Is HDR better?. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1629.	0.4	0

#	ARTICLE	IF	CITATIONS
595	Response to editorial by Drs. Lanciano and corn. International Journal of Radiation Oncology Biology Physics, 1993, 27, 991.	0.4	0
596	Glioblastoma multiforme: "who should receive stereotactic boost therapy?" International Journal of Radiation Oncology Biology Physics, 1994, 30, 746.	0.4	0
597	Manpower issues and training program directions in radiation oncology. International Journal of Radiation Oncology Biology Physics, 1996, 34, 970.	0.4	0
598	214 Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. International Journal of Radiation Oncology Biology Physics, 1997, 39, 123.	0.4	0
599	19 Feasibility & acute toxicities of craniospinal hyperfractionated radiotherapy (CHFRT) for high risk intracranial primitive neuroectodermal tumors (HRPNET); CCG-9931; A groupwise phase II study of intensive chemotherapy (CT) & CHFRT. International Journal of Radiation Oncology Biology Physics, 1997, 39, 144.	0.4	0
600	1021 Optic nerve tolerance to single and fractionated radiation simulating radiosurgery: A rabbit model using visual evoked potentials, fundoscopy and histology. International Journal of Radiation Oncology Biology Physics, 1997, 39, 226.	0.4	0
601	1034 Experience with the functional assessment of cancer therapy-lung (FACT-L) in ecog 4593, a phase II hyperfractionated accelerated radiation therapy (HART) trial. International Journal of Radiation Oncology Biology Physics, 1997, 39, 232.	0.4	0
602	On "Stereotactic Radiosurgery for Patients with Single Brain Metastasis" (Cho et al., This Issue). Journal of Radiosurgery, 1998, 1, 87-88.	0.1	0
603	Retrospective vs. randomized data: the prevalence of bias. in response to Drs. Millar and Laperriere. International Journal of Radiation Oncology Biology Physics, 2002, 53, 252-253.	0.4	0
604	E-53. Helical tomotherapy: An innovative technological radiation therapeutic approach for lung cancer. Lung Cancer, 2003, 41, S67-S68.	0.9	0
605	In response to Drs. Vordermark and KÄ¶hl. International Journal of Radiation Oncology Biology Physics, 2005, 62, 297.	0.4	0
606	1115. International Journal of Radiation Oncology Biology Physics, 2006, 66, S196.	0.4	0
607	B1-07: Decreased neurocognitive progression with Motexafin Gadolinium (MGd) plus Whole Brain Radiation Therapy (WBRT) in non-small cell lung cancer (NSCLC) patients with brain metastases: pooled analysis of two randomized phase 3 trials. Journal of Thoracic Oncology, 2007, 2, S335-S336.	0.5	0
608	PD5-2-8: Predictors of survival for non-small-cell lung cancer patients with brain metastases treated with whole brain radiation therapy: pooled data from two randomized trials. Journal of Thoracic Oncology, 2007, 2, S478.	0.5	0
609	Adaptive Tomotherapy Planning for Integrated Boost Doses in Rapidly Responding Lung Cancers. International Journal of Radiation Oncology Biology Physics, 2007, 69, S525.	0.4	0
610	The Prognostic Value of Nestin Expression in Newly Diagnosed GBM: Report from the RTOG. International Journal of Radiation Oncology Biology Physics, 2008, 72, S206.	0.4	0
611	In Reply to Drs. Nieder and Molls. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1619.	0.4	0
612	In Reply to Drs. Weltman and Brandt. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1292-1293.	0.4	0

#	ARTICLE	IF	CITATIONS
613	Treatment-Related Pneumonitis and Acute Esophagitis in Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy and Helical Tomotherapy: In Regard to Song etÂal.. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1281.	0.4	0
614	Brain Metastases. Medical Radiology, 2010, , 209-223.	0.0	0
615	Reply to Drs. Mulvenna and Holt. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1194-1195.	0.4	0
616	Predictive Value of Tumor Recurrence using Urinary Vascular Endothelial Growth Factor Levels in Patients Receiving Radiation Therapy for Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S181.	0.4	0
617	Pro: Lung Cancer in 2011: A Time for Optimism and Investment in New Approaches and Technologies with a Commitment to Produce Evidence-Based Data. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1231-1234.	2.5	0
618	Advances in Radiation Oncology of Lung Cancer. Medical Radiology, 2011, , 725-733.	0.0	0
619	In regards to Kirby <i>et al</i> . âœPhysics strategies for sparing neural stem cells during whole-brain radiation treatments,â€[Med. Phys. 38, 5338 (2011)]. Medical Physics, 2012, 39, 1677-1678.	1.6	0
620	The Effect of Tumor Subtype on the Time From Primary Diagnosis to Development of Brain Metastases and Survival in Women With Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, S142.	0.4	0
621	Cilengitide Inhibits Proliferation and Shows Combined Effects With Radiation in Breast Cancer Cell Lines. International Journal of Radiation Oncology Biology Physics, 2013, 87, S658.	0.4	0
622	Large Tumor Size Increases the Risk of Developing Symptomatic Pleural Effusions Following Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S664.	0.4	0
623	Comparison of Coronary Vessel Contouring Using Non-Contrast Cardiac Gated CT Versus CT Angiogram. International Journal of Radiation Oncology Biology Physics, 2014, 90, S263.	0.4	0
624	Real-Time Pretreatment Review Limits Unacceptable Deviations: Quality Assurance (QA) Results of RTOG 0933. International Journal of Radiation Oncology Biology Physics, 2014, 90, S318.	0.4	0
625	Application of a Survival-Predicting Nomogram Based Primarily on Whole-Brain Radiation Therapyâ€Treated Patients With Brain Metastases Yields Significant Underestimates for Radiosurgery-Treated Patients. International Journal of Radiation Oncology Biology Physics, 2014, 90, S911.	0.4	0
626	NCO-14PRE-TREATMENT HIPPOCAMPAL VOLUME PREDICTS NEUROCOGNITIVE FUNCTION (NCF) FOR PATIENTS TREATED WITH HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0933. Neuro-Oncology, 2015, 17, v149.1-v149.	0.6	0
627	BMET-20RTOG1119 PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868). Neuro-Oncology, 2015, 17, v49.2-v49.	0.6	0
628	RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825. Neuro-Oncology, 2015, 17, v195.3-v195.	0.6	0
629	OP02ADOLESCENT/YOUNG ADULT MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT STRATEGY. Neuro-Oncology, 2015, 17, viii16.2-viii16.	0.6	0
630	ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525. Neuro-Oncology, 2015, 17, v8.1-v8.	0.6	0

#	ARTICLE	IF	CITATIONS
631	Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825. International Journal of Radiation Oncology Biology Physics, 2015, 93, S110.	0.4	0
632	RTRB-14 TREATMENT RECOMMENDATIONS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA LACK WORLDWIDE CONSENSUS. Neuro-Oncology, 2015, 17, v198.2-v198.	0.6	0
633	Whole-Brain Radiotherapy for Brain Metastases: Is the Therapeutic Window Enlarging?. , 2015, , 41-56.		0
634	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2015, 33, 1986-1986.	0.8	0
635	Comparison of Overall Survival for Esophageal Cancer Patients Treated With Neoadjuvant Proton or Photon Chemoradiation: A Multi-institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 93, S13-S14.	0.4	0
636	Clinical Outcomes for Esophageal Cancer Patients Treated With Intensity Modulated Radiation Therapy Compared to 3-D Conformal Radiation Therapy: An Analysis of the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2015, 93, E165-E166.	0.4	0
637	Fact or Fiction: Proton Beam Therapy is Primarily for Patients With Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, E353-E354.	0.4	0
638	Volumetric Analysis of the Hippocampus in Long Term ($\hat{\approx}$ 1 year) Survivors of Whole Brain-Radiation Therapy for Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2015, 93, E69.	0.4	0
639	Minimal Early Increase in Contrast Enhancement After Chemoradiation Therapy for Glioblastoma Predicts Worse Overall and Progression Free Survival. International Journal of Radiation Oncology Biology Physics, 2015, 93, E106-E107.	0.4	0
640	METIS: A phase III study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC. Annals of Oncology, 2016, 27, vi113.	0.6	0
641	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2016, 34, 4057-4057.	0.8	0
642	Improving Radiation Oncology Residency Structure: A Multi-Institutional Survey Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, E417.	0.4	0
643	Impact of Age on Early Volumetric Changes in Adults with Low-Grade or Benign Intracranial Neoplasms Treated With External Beam Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E83.	0.4	0
644	A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813. International Journal of Radiation Oncology Biology Physics, 2016, 96, S91.	0.4	0
645	Multi-institutional Validation of a Novel Glioblastoma Prognostic Nomogram Incorporating MGMT Methylation. International Journal of Radiation Oncology Biology Physics, 2016, 96, S182.	0.4	0
646	Brain Metastases. Medical Radiology, 2016, , 337-356.	0.0	0
647	Clinical Outcomes of Patients with Stage II-III Non-Small Cell Lung Cancer (NSCLC) Treated with Proton Beam Therapy (PBT) on the Proton Collaborative Group (PCG) Prospective Registry Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, E434-E435.	0.4	0
648	Robust Lymph Nodes Proton Scanning Irradiation for Locally Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E682.	0.4	0

#	ARTICLE	IF	CITATIONS
649	Future Directions for Tumor Treating Fields. , 2016, , 117-126.		0
650	P2.06-034 METIS: A Phase 3 Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC. Journal of Thoracic Oncology, 2017, 12, S1092-S1093.	0.5	0
651	Radiation Therapy in the Treatment of Low Grade Gliomas. , 2017, , 579-594.		0
652	State of the art: the evolving role of RT in combined modality therapy for GBM. Journal of Neuro-Oncology, 2017, 134, 477-478.	1.4	0
653	Brain Metastases in Lung Cancer With Targetable Mutationsâ€™Reply. JAMA Oncology, 2018, 4, 422.	3.4	0
654	Dosimetric Impact of Large Displacement of the Metal Port of the Tissue Expander in Intensity Modulated Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, S183.	0.4	0
655	Survival and Prognostic Factors in Patients with Gastrointestinal Cancers and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 102, e314-e315.	0.4	0
656	Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?. Journal of Clinical Oncology, 2018, 36, 3277-3281.	0.8	0
657	Glioblastoma. , 2019, , 237-247.		0
658	Radiotherapy innovations to optimize brain metastases control. Neuro-Oncology, 2020, 22, 1715-1717.	0.6	0
659	Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes. Neuro-Oncology, 2020, 22, 1062-1064.	0.6	0
660	RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis. Neuro-Oncology Advances, 2021, 3, iii20-iii20.	0.4	0
661	OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. Neuro-Oncology Advances, 2021, 3, iii15-iii16.	0.4	0
662	A prospective multidisciplinary review of radiotherapy processes during the telemedicine era.. Journal of Clinical Oncology, 2021, 39, 282-282.	0.8	0
663	Basic Concepts Underlying Radiation Therapy. , 2005, , 70-74.		0
664	SU-FF-T-369: Propagation of Linac Output and Fluence Discretization Error to Dose Distributions in IMRT. Medical Physics, 2006, 33, 2130-2131.	1.6	0
665	Advances in the Treatment of Brain Metastases. Translational Medicine Series, 2007, , 207-230.	0.0	0
666	Stereotactic Body Radiation Therapy: Fractionated Radiation Therapy Perspective. , 2008, , 635-642.		0

#	ARTICLE	IF	CITATIONS
667	Cost-Effectiveness and Quality of Life. , 2008, , 663-671.		0
668	Dose-Escalated High-Precision Radiotherapy: a Method to Overcome Variations in Biology and Radiosensitivity Limiting the Success of Conventional Approaches?. Medical Radiology, 2009, , 335-346.	0.0	0
669	Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.. , 2013, , .		0
670	Phase II study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.. Journal of Clinical Oncology, 2014, 32, 2072-2072.	0.8	0
671	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. International Journal of Particle Therapy, 2016, 2, 555-569.	0.9	0
672	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.. Journal of Clinical Oncology, 2016, 34, 2007-2007.	0.8	0
673	SU-F-T-188: A Robust Treatment Planning Technique for Proton Pencil Beam Scanning Cranial Spinal Irradiation. Medical Physics, 2016, 43, 3505-3505.	1.6	0
674	Abstract CT151: TTFIELDS and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study. , 2018, , .		0
675	Insight into the brain metastasis journey: Initial survey results from patients and caregivers.. Journal of Clinical Oncology, 2019, 37, 2069-2069.	0.8	0
676	Incidence of rib fractures after stereotactic body radiotherapy for peripheral lung lesions: clinical experience and dose response estimation. Journal of Radiosurgery and SBRT, 2011, 1, 155-161.	0.2	0
677	Prognostic factors for complete obliteration of arteriovenous malformations treated with LINAC-based stereotactic radiosurgery. Journal of Radiosurgery and SBRT, 2011, 1, 203-211.	0.2	0
678	Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method. Journal of Radiosurgery and SBRT, 2011, 1, 221-229.	0.2	0
679	Optimizing the Radiotherapy Treatment Planning Process for Glioblastoma. Neuro-Oncology Practice, 0, , .	1.0	0